Glucotrack, Inc. (GCTK) · Oct 22, 2026 · New debt

Glucotrack financing buys time as dilution and delisting risks mount

$2M secured financing — 22% OID; 8% coupon; 9-month maturity

Glucotrack’s new financing provides $2 million of cash, but expensive secured debt, heavy warrant coverage and a Nasdaq compliance deadline raise pressure.

Glucotrack is still financing development of an investigational implantable continuous glucose monitor while trying to preserve its Nasdaq listing; the CBGM remains a development-stage product rather than a commercial revenue engine.

The financing extends runway, but only modestly. Glucotrack received $2.0 million of gross cash while issuing notes with $2.564 million of principal, before placement fees and other expenses. The 22% original issue discount means the company is effectively borrowing substantially more than it receives, with 8% annual interest and a nine-month maturity. 〔0〕

Investors received unusually strong downside protection. The notes are senior, secured by substantially all company and subsidiary assets, and rank equally with existing secured obligations. 〔1〕 The deal also gives investors first claim on proceeds from future financings and requires 50% of equity-line proceeds to repay the notes, limiting Glucotrack’s flexibility to fund the device program through additional capital raises.

The potential dilution is large relative to the current share base. Investors received warrants for 8.03 million shares, versus 2.37 million shares outstanding before the transaction. The notes can convert at the lower of $0.639 or 80% of a trailing VWAP, subject to a floor initially equal to $0.1278, creating a structure where a weaker share price can increase the number of shares issued. The 19.99% exchange cap delays issuance above Nasdaq’s threshold unless shareholders approve it; the company must file a proxy within 30 days and seek approval within 90 days.

The reverse split is a listing-preservation measure, not a business advance. Glucotrack will implement a 1-for-2 split on October 26, following a 1-for-15 split on August 28. It is intended to lift the share price above Nasdaq’s minimum bid requirement, but the company still must maintain a closing bid of at least $1.00 through November 9.

Bottom line: This financing keeps the company funded in the near term, but it does so through expensive secured debt and substantial potential dilution. The reverse split addresses an immediate listing threat; neither action advances the underlying glucose-monitoring technology itself.

What to watch next

Registration filing due within 10 days; Nasdaq test ends November 9

Original filing on SEC EDGAR

More Glucotrack, Inc. news

Glucotrack financing buys time as dilution and delisting risks mount | GCTK Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.